NASDAQ:FGEN - FibroGen, Inc.
$46.43
 $0.83
+1.82%
4:00PM EDT
2019-07-15
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Companys most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  FGEN     avg for
industry  
  avg for
sector  
42 stocks weight:  64. 44   114. 77   204. 78  
42 stocks rank:  2. 02 K 1. 44 K 810. 33  
# analyst opinions:  7. 00   13. 59   13. 86  
mean recommendation:  1. 90   2. 12   2. 04  

quick ratio:  6. 08   5. 48   1. 89  
current ratio:  6. 17   5. 85   2. 40  

target price low:  40. 00   82. 72   115. 11  
target price avg:  63. 71   104. 42   138. 02  
target price high:  85. 00   130. 64   159. 47  
1-yr high:  66. 40   110. 27   142. 72  
last close:  45. 60   85. 12   126. 54  
50-day avg:  41. 18   86. 06   122. 35  
200-day avg:  47. 72   88. 76   121. 75  
1-yr low:  35. 13   69. 26   100. 63  
volume:  341. 51 K 3. 51 M 5. 53 M
50-day avg volume:  911. 43 K 3. 21 M 4. 22 M
200-day avg volume:  726. 14 K 3. 04 M 4. 75 M

1-day return:  0. 93 % -0. 30 % -1. 01 %
this week return:  2. 86 % -2. 16 % -1. 35 %
12-wk return:  -3. 41 % 3. 34 % 8. 69 %
52-wk return:  -31. 10 % -1. 76 % 12. 22 %

enterprise value (EV):  3. 40 B 46. 50 B 123. 99 B
market cap:  3. 93 B 40. 77 B 109. 11 B
EBITDA:  -84. 58 M 4. 33 B 8. 19 B
enterprise multiple (EV/EBITDA):  -40. 15   5. 45   12. 05  
enterprise/revenue (EV/R):  16. 57   50. 46   9. 50  
total revenue:  204. 90 M 10. 21 B 40. 60 B
total debt:  77. 14 M 11. 27 B 17. 58 B
debt/equity:  15. 17   57. 36   120. 25  
net income (common):  -90. 44 M 2. 13 B 4. 27 B

shares outstanding:  83. 42 M 551. 08 M 1. 24 B
shares:  77. 39 M 559. 41 M 1. 22 B
shares short:  5. 44 M 11. 15 M 11. 94 M
shares short prior month:  4. 34 M 9. 31 M 11. 96 M
short ratio:  6. 45   5. 72   3. 43  
short % of float:  7. 60 % 6. 40 % 2. 65 %
total cash/share:  6. 56   11. 00   9. 23  
total cash:  565. 40 M 6. 03 B 6. 01 B
free cash flow:  -5. 40 M 3. 02 B 4. 96 B
operating cash flow:  -21. 70 M 3. 92 B 5. 99 B

book value:  5. 68   13. 02   27. 49  
price/book:  8. 03   4. 21   8. 80  
gross profits:  -22. 88 M 7. 67 B 36. 29 B
operating margins:  -46. 33 % -380. 20 % -38. 44 %
EBITDA margins:  -41. 28 % 13. 59 % 23. 24 %
profit margins:  -44. 14 % 10. 94 % 14. 00 %
gross margins:  -11. 94 % 36. 11 % 55. 16 %

1-yr max volatility:  20. 20 % --- ---
1-yr mean volatility:  2. 33 % 1. 50 % 1. 08 %

1-yr EPS:  -1. 07   2. 12   4. 26  
forward EPS:  -0. 04   3. 47   7. 14  
P/E:  -42. 74   2. 15   33. 17  
forward P/E:  -1. 13 K -4. 03   17. 60  
PE/G:  1. 69   0. 54   0. 34  
growth:  -25. 30 % 263. 03 % 78. 34 %
earnings high:  0. 46   0. 91   1. 70  
earnings avg:  -0. 37   0. 71   1. 58  
earnings low:  -0. 74   0. 48   1. 46  
revenue high:  119. 25 M 2. 64 B 11. 26 B
revenue avg:  42. 78 M 2. 58 B 11. 09 B
revenue low:  17. 50 M 2. 54 B 10. 90 B
return on assets:  -7. 06 % -2. 31 % 5. 31 %
return on equity:  -17. 61 % -82. 48 % 135. 30 %
revenue growth:  -25. 30 % 262. 60 % 72. 94 %
revenue/share:  2. 42   12. 77   61. 38  

beta (1yr vs S&P500):  1. 73   1. 26   0. 91  
sharpe (1yr):  -0. 40   0. 07   0. 77  

held % insiders:  10. 92 % 6. 08 % 3. 31 %
held % institutions:  66. 88 % 78. 36 % 69. 61 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-14 : FGEN
.    145.369 =       145.369 :: --> INITIAL WEIGHT <--
.    - 1.067 =       144.302 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.728 =       393.695 :: P/E factor
.    x 0.955 =       376.122 :: PE/G factor
.     x 1.57 =        590.55 :: beta factor
.     x 0.78 =       460.801 :: sharpe factor
.    x 2.947 =      1357.902 :: current ratio factor
.    x 1.094 =      1485.458 :: quick ratio factor
.    x 1.075 =      1596.462 :: short ratio factor
.    x 1.328 =      2120.767 :: EV/R factor
.    x 1.092 =      2315.485 :: price-to-book factor
.    x 2.656 =      6150.532 :: debt-to-revenue factor
.    x 1.124 =      6916.221 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.114 =     14620.783 :: sector+industry 1-year gains factor
.    x 1.033 =     15109.088 :: industry 12-weeks return factor
.    x 1.305 =     19721.495 :: industry 2-weeks return factor
.    x 0.932 =     18382.944 :: company one-year gains+dividend factor
.     x 3.64 =     66919.932 :: company 13 weeks' performance factor
.    x 1.357 =     90813.385 :: 5-day avg > 50-day avg
.     x 0.98 =     88999.429 :: "drift" penalty 1 days ago
.    x 0.989 =     88058.507 :: "drift" penalty 2 days ago
.    / 1.927 =     45690.287 :: overall "drift" factor
.    x 0.935 =     42736.372 :: largest single-day jump factor
.    x 0.992 =     42374.375 :: volatility factor
.    x 0.993 =     42081.599 :: 42-day volatility factor
.    x 3.773 =    158782.719 :: notable returns + performance factor
.    x 4.522 =    717957.694 :: performance vs s&p500 factor
.    x 3.763 =   2701760.771 :: inverse volume-to-price factor
.                               --> PROJECTIONS <--
.     x 0.04 =    108070.431 :: forward EPS factor
.    x 0.651 =     70370.599 :: forward P/E factor
.    x 1.182 =     83209.635 :: industry recommendation factor
.    x 2.331 =    193998.554 :: company recommendation factor
.    x 1.008 =    195482.321 :: factor historical industry gain for week 28
.    x 0.947 =    185027.185 :: target low factor
.     x 1.21 =    223895.087 :: target mean factor
.    x 1.039 =    232636.055 :: target high factor
.   x 10.301 =    2396359.22 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        39.345 :: reduced for readability
.   + 25.055 =          64.4 :: add/subtract for investor sentiment
.    + 0.038 =        64.437 :: earnings report in 19 days
.                               --> FINAL WEIGHT <--
.                     64.437 :: FINAL WEIGHT for NASDAQ:FGEN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org